Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 0.62 |
| ▸ | SRD5A1 | P18405 | 2/20 | 0.50 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.43 |
| ▸ | PARP11 | Q9NR21 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | BRAF | P15056 | 6/20 | 0.43 |
| ▸ | MAPK3 | P27361 | 5/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 5/20 | 0.43 |
| ▸ | CYP19A1 | P11511 | 6/20 | 0.41 |
| ▸ | CYP11B1 | P15538 | 6/20 | 0.41 |
| ▸ | CYP11B2 | P19099 | 6/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2306868 | 1.00 | HTT (0.62) | HTTSRD5A1SRD5A2LMNAHSD17B10 | |
| SCHEMBL11898554 | 1.00 | HTT (0.62) | HTTSRD5A1SRD5A2LMNAHSD17B10 | |
| SCHEMBL1809334 | 0.89 | HPGD (0.53) | HTTSRD5A1SRD5A2PARP10PARP11 | |
| SCHEMBL16621035 | 0.89 | HPGD (0.53) | HTTSRD5A1SRD5A2PARP10PARP11 | |
| SCHEMBL11971363 | 0.89 | HPGD (0.53) | HTTSRD5A1SRD5A2PARP10PARP11 | |
| SCHEMBL595554 | 0.85 | HTT (0.49) | HTTSRD5A1SRD5A2LMNAHSD17B10 | |
| SCHEMBL595553 | 0.85 | HTT (0.49) | HTTSRD5A1SRD5A2LMNAHSD17B10 | |
| SCHEMBL595555 | 0.85 | HTT (0.49) | HTTSRD5A1SRD5A2LMNAHSD17B10 | |
| SCHEMBL204100 | 0.79 | SRD5A1 (0.64) | SRD5A1SRD5A2PARP10PARP11L3MBTL1 | |
| SCHEMBL31268305 | 0.79 | SRD5A1 (0.64) | SRD5A1SRD5A2PARP10PARP11L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 62 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-105175272-A | Method for preparing R-5-bromo-1-aminoindane | WU LING | 2015-12-23 | — | — | CN | claimed |
| CN-105130824-A | Method for preparing S-5-bromo-1-aminoindane | WU LING | 2015-12-09 | — | — | CN | claimed |
| US-20230255200-A1 | USE OF STROBILURIN TYPE COMPOUNDS FOR COMBATING PHYTOPATHOGENIC FUNGI CONTAINING AN AMINO ACID SUBSTITUTION F129L IN THE MITOCHONDRIAL CYTOCHROME B PROTEIN CONFERRING RESISTANCE TO QO INHIBITORS VI | BASF SE (DE) | 2023-08-17 | — | — | US | disclosed |
| EP-4178943-A1 | USE OF STROBILURIN TYPE COMPOUNDS FOR COMBATING PHYTOPATHOGENIC FUNGI CONTAINING AN AMINO ACID SUBSTITUTION F129L IN THE MITOCHONDRIAL CYTOCHROME B PROTEIN CONFERRING RESISTANCE TO QO INHIBITORS VI | BASF SE (DE) | 2023-05-17 | — | — | EP | disclosed |
| CN-115836049-A | Use of strobilurin-type compounds to control phytopathogenic fungi containing the amino acid substitution F129L in the mitochondrial cytochrome b protein conferring tolerance to Qo inhibitor VI | 巴斯夫欧洲公司 | 2023-03-21 | — | — | CN | disclosed |
| EP-3960727-A1 | USE OF STROBILURIN TYPE COMPOUNDS FOR COMBATING PHYTOPATHOGENIC FUNGI CONTAINING AN AMINO ACID SUBSTITUTION F129L IN THE MITOCHONDRIAL CYTOCHROME B PROTEIN CONFERRING RESISTANCE TO QO INHIBITORS VI | BASF SE (DE) | 2022-03-02 | — | — | EP | disclosed |
| WO-2022008303-A1 | USE OF STROBILURIN TYPE COMPOUNDS FOR COMBATING PHYTOPATHOGENIC FUNGI CONTAINING AN AMINO ACID SUBSTITUTION F129L IN THE MITOCHONDRIAL CYTOCHROME B PROTEIN CONFERRING RESISTANCE TO QO INHIBITORS VI | BASF SE (DE) | 2022-01-13 | — | — | WO | disclosed |
| US-9809553-B2 | Isoquinoline compounds, a process for their preparation, and pharmaceutical compositions containing them | LES LABORATOIRES SERVIER (FR) | 2017-11-07 | — | — | US | disclosed |
| US-20170137385-A1 | ISOQUINOLINE COMPOUNDS, A PROCESS FOR THEIR PREPARATION, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | LES LABORATOIRES SERVIER (FR) | 2017-05-18 | — | — | US | disclosed |
| EP-3095780-A1 | PESTICIDAL ARYLPYRROLIDINES | Bayer Intellectual Property GmbH (DE) | 2016-11-23 | — | — | EP | disclosed |
| US-9271499-B2 | Pesticidal arylpyrrolidines | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2016-03-01 | — | — | US | disclosed |
| WO-2010043315-A1 | PESTICIDAL (HETERO) ARYLPYRROLIDINES | BAYER CROPSCIENCE AG (DE) | 2010-04-22 | — | — | WO | disclosed |
| US-20090137547-A1 | Heterobicyclic metalloprotease inhibitors | ALANTOS PHARMACEUTICALS HOLDING, INC. | 2009-05-28 | — | — | US | disclosed |
| US-7414142-B2 | 5-aryl-indan-1-one oximes and analogs useful as progesterone receptor modulators | WYETH (US) | 2008-08-19 | — | — | US | disclosed |
| CN-101137414-A | Multicyclic bis-amide mmp inhibitors | ALANTOS PHARMACEUTICALS INC (US) | 2008-03-05 | — | — | CN | disclosed |
| EP-1843820-A1 | MULTICYCLIC BIS-AMIDE MMP INHIBITORS | Alantos Pharmaceuticals, Inc. (US) | 2007-10-17 | — | — | EP | disclosed |
| US-20070066637-A1 | 5-Aryl-indan-1-one oximes and analogs useful as progesterone receptor modulators | WYETH (US) | 2007-03-22 | — | — | US | disclosed |
| WO-2006083454-A1 | MULTICYCLIC BIS-AMIDE MMP INHIBITORS | ALANTOS PHARMACEUTICALS, INC. (US) | 2006-08-10 | — | — | WO | disclosed |
| US-20060173183-A1 | Multicyclic bis-amide MMP inhibitors | ALANTOS PHARMACEUTICALS, INC., | 2006-08-03 | — | — | US | disclosed |
| WO-1996036596-A1 | 3,4-DISUBSTITUTED-PHENYLSULPHONAMIDES AND THEIR THERAPEUTIC USE | CHIROSCIENCE LIMITED (GB) | 1996-11-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060173183-A1 | Multicyclic bis-amide MMP inhibitors | MMP13, MMP3, MMP11 | HTT 2111/4885SRD5A1 4641/4885SRD5A2 4656/4885 |
| US-20170137385-A1 | ISOQUINOLINE COMPOUNDS, A PROCESS FOR THEIR PREPARATION, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | MYLK, MYLK2, MYLK3 | HTT 3543/4885SRD5A1 3199/4885SRD5A2 3288/4885 |
| US-20090137547-A1 | Heterobicyclic metalloprotease inhibitors | MMP13, TIMP3, MMP3 | HTT 2315/4885SRD5A1 3637/4885SRD5A2 3698/4885 |
| US-20070066637-A1 | 5-Aryl-indan-1-one oximes and analogs useful as progesterone receptor modulators | CYP19A1, PGR, GNRHR | HTT 4288/4885SRD5A1 31/4885SRD5A2 38/4885 |
| US-20230255200-A1 | USE OF STROBILURIN TYPE COMPOUNDS FOR COMBATING PHYTOPATHOGENIC FUNGI CONTAINING AN AMINO ACID SUBSTITUTION F129L IN THE MITOCHONDRIAL CYTOCHROME B PROTEIN CONFERRING RESISTANCE TO QO INHIBITORS VI | COX5B, SQOR, COX6B1 | HTT 2864/4885SRD5A1 1299/4885SRD5A2 1682/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.